Cite
Safety and tolerability of T-SIGn vectors when administered using 'flat' versus 'low-high-high' (LHH) dosing regimens
MLA
Thomas Lillie, et al. “Safety and Tolerability of T-SIGn Vectors When Administered Using ‘Flat’ versus ‘Low-High-High’ (LHH) Dosing Regimens.” Journal of Clinical Oncology, vol. 40, June 2022, p. 2572. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ac5d1f5a92e982a1d621f93bd88b02a1&authtype=sso&custid=ns315887.
APA
Thomas Lillie, Lee S. Rosen, David Krige, Minesh Patel, Isabel Prieto González-Albo, Jo Carter, Behnaz Ravanfar, Vladimir Evilevitch, & Aung Naing. (2022). Safety and tolerability of T-SIGn vectors when administered using “flat” versus “low-high-high” (LHH) dosing regimens. Journal of Clinical Oncology, 40, 2572.
Chicago
Thomas Lillie, Lee S. Rosen, David Krige, Minesh Patel, Isabel Prieto González-Albo, Jo Carter, Behnaz Ravanfar, Vladimir Evilevitch, and Aung Naing. 2022. “Safety and Tolerability of T-SIGn Vectors When Administered Using ‘Flat’ versus ‘Low-High-High’ (LHH) Dosing Regimens.” Journal of Clinical Oncology 40 (June): 2572. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ac5d1f5a92e982a1d621f93bd88b02a1&authtype=sso&custid=ns315887.